Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Puretech Health Plc (PRTC)
:PRTC
Holding PRTC?
Track your performance easily
PRTC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.00 - $34.00
Previous CloseN/A
Volume2.03K
Average Volume (3M)4.92K
Market Cap
$414.52M
Enterprise Value$448.27M
Total Cash (Recent Filing)$12.03M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Apr 24, 2025EPS Estimate
-2.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.02
Shares Outstanding23,942,131
10 Day Avg. Volume4,262
30 Day Avg. Volume4,920
Standard Deviation0.14
R-Squared0.17
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)553.44
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit134.62
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$46.00Price Target Upside162.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
PureTech Health News
Bulls Say, Bears Say
Bulls Say
Business ModelThe hybrid business model of Puretech Health Plc, combining drug development and company incubation, offers multiple ways to succeed over the long term.
Drug DevelopmentLYT-100 is seen as the most promising wholly-owned program within Puretech Health Plc, demonstrating potential as a real drug in the high unmet need and large market opportunity in IPF.
Research And DevelopmentPRTC's 'Hub-and-Spoke' R&D model offers a multitude of growth opportunities in a capital-efficient and risk-sharing manner.
Bears Say
Market AccessibilityThe unique business model and low liquidity for US-listed shares create a barrier to entry for some investors.
Product EfficacyLYT-100 550mg shows more tolerability than pirfenidone, though with modestly lower efficacy, which may limit its appeal.
Stock PerformancePRTC stock continues to be dislocated due to investor base turnover and low liquidity for the ADRs.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
0.12% Other Institutional Investors
99.88% Public Companies and
Individual Investors
PRTC FAQ
What was Puretech Health Plc’s price range in the past 12 months?
Puretech Health Plc lowest stock price was $17.00 and its highest was $34.00 in the past 12 months.
What is Puretech Health Plc’s market cap?
Puretech Health Plc’s market cap is $414.52M.
When is Puretech Health Plc’s upcoming earnings report date?
Puretech Health Plc’s upcoming earnings report date is Apr 24, 2025 which is in 92 days.
How were Puretech Health Plc’s earnings last quarter?
Puretech Health Plc released its earnings results on Aug 28, 2024. The company reported -$1.5 earnings per share for the quarter, beating the consensus estimate of -$3.03 by $1.53.
Is Puretech Health Plc overvalued?
According to Wall Street analysts Puretech Health Plc’s price is currently Undervalued.
Does Puretech Health Plc pay dividends?
Puretech Health Plc does not currently pay dividends.
What is Puretech Health Plc’s EPS estimate?
Puretech Health Plc’s EPS estimate is -2.83.
How many shares outstanding does Puretech Health Plc have?
Puretech Health Plc has 23,942,131 shares outstanding.
What happened to Puretech Health Plc’s price movement after its last earnings report?
Puretech Health Plc reported an EPS of -$1.5 in its last earnings report, beating expectations of -$3.03. Following the earnings report the stock price went down -6%.
Which hedge fund is a major shareholder of Puretech Health Plc?
Currently, no hedge funds are holding shares in PRTC
---
PureTech Health Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.00 (162.86% Upside)
$46.00 (162.86% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.08%
12-Months-Change
Fundamentals
Return on Equity
-19.80%
Trailing 12-Months
Asset Growth
-16.38%
Trailing 12-Months
Company Description
Puretech Health Plc
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on areas of growing scientific and technical insights that it believes are at an important inflection point, including the central nervous, gastrointestinal and immune systems, and the interactions and signaling between them. The company has a robust pipeline of advanced programs that are post-human proof of concept, focused on addressing some of the society's healthcare needs.
---
PRTC Earnings Call
Q2 2024
0:00 / 0:00
---
PRTC Stock 12 Month Forecast
Average Price Target
$46.00
▲(162.86% Upside)
Technical Analysis
Seres Therapeutics
―
Gritstone bio
―
Alaunos Therapeutics
―
Adaptimmune Therapeutics
―
Scholar Rock Holding
―
Bristol-Myers Squibb
―
Best Analysts Covering PRTC
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-19.30%
reiterated a buy rating last month
Copying Faisal Khurshid's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -19.30% per trade.
---